Viracta Therapeutics Inc. is a biopharmaceutical company focusing on the development and commercialization of innovative therapies for the treatment of viral-associated cancers. Its proprietary drug, nanatinostat, in combination with valganciclovir, is being evaluated for the therapy of Epstein-Barr virus-associated lymphomas. The company aims to improve the lives of cancer patients by targeting the underlying viral causes of their diseases.
